Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Gains from Investment Securities: 2016-2024

Historic Gains from Investment Securities for Solid Biosciences (SLDB) over the last 9 years, with Dec 2024 value amounting to $407,000.

  • Solid Biosciences' Gains from Investment Securities was N/A to -$10,000 in Q2 2024 from the same period last year, while for Jun 2024 it was -$106,000, marking a year-over-year change of. This contributed to the annual value of $407,000 for FY2024, which is 81.99% down from last year.
  • Latest data reveals that Solid Biosciences reported Gains from Investment Securities of $407,000 as of FY2024, which was down 81.99% from $2.3 million recorded in FY2023.
  • Solid Biosciences' Gains from Investment Securities' 5-year high stood at $3.1 million during FY2020, with a 5-year trough of $400,842 in FY2021.
  • Its 3-year average for Gains from Investment Securities is $1.4 million, with a median of $1.4 million in 2022.
  • In the last 5 years, Solid Biosciences' Gains from Investment Securities tumbled by 87.14% in 2021 and then soared by 257.74% in 2022.
  • Over the past 5 years, Solid Biosciences' Gains from Investment Securities (Yearly) stood at $3.1 million in 2020, then plummeted by 87.14% to $400,842 in 2021, then skyrocketed by 257.74% to $1.4 million in 2022, then spiked by 57.58% to $2.3 million in 2023, then slumped by 81.99% to $407,000 in 2024.